2yr
Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37271601/
Treatment in a lipid clinic leads to a superior LDL-C goal achievement in very high-risk CVD patients as compared to standard care with the highest reduction under LLT with high-intensity statins and ezetimibe. Referral algorithms have to be established for high-risk patients.
Conclusion: Treatment in a lipid clinic leads to a superior LDL-C goal achievement in very high-risk CVD patients as compared to standard care with the highest reduction under LLT with high-intensity statins and ezetimibe. Referral algorithms have to be established for high-risk patients.
Share
• Source: Journal of Clinical Lipidology
• Conclusions/Relevance: “Lipid-lowering therapy (LLT) in patients with cardiovascular disease (CVD) is insufficient despite clear guideline recommendations. Lipid clinics have specialized in patients with dyslipidemia, but the magnitude and reduction of low-density lipoprotein cholesterol (LDL-C) in lipid clinics has not yet been studied in depth …. Treatment in a lipid clinic leads to a superior LDL-C goal achievement in very high-risk CVD patients as compared to standard care with the highest reduction under LLT with high-intensity statins and ezetimibe. Referral algorithms have to be established for high-risk patients.”
• German researchers examined LDL-C reduction in very high-risk CVD patients treated in a specialized lipid clinic using different types of lipid-lowering therapy (LLT) vs standard of care without the initiation of PSCK9 inhibitors. They focused on combinations of statins and ezetimibe.
• In total, the attainment of LDL-C goals went from14.6% at baseline to 41.7% at the latest visit (P < ). These rates improved from 21.4% to 33.3% in standard of care patients (P = 0.08). The initiation of high-intensity statins resulted in the largest reduction in LDL-C levels.